Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Suchergebnisse

Is MasterCard (MA) a Solid Growth Stock? 3 Reasons to Think "Yes"
Is MasterCard (MA) a Solid Growth Stock? 3 Reasons to Think "Yes"

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to

KYMR Stock Up as FDA Grants Fast Track Designation to Asthma Drug
KYMR Stock Up as FDA Grants Fast Track Designation to Asthma Drug

Kymera Therapeutics KYMR announced that the FDA has granted a Fast Track designation to its lead candidate, KT-621, for the treatment of moderate-to-severe eosinophilic asthma. KYMR shares rose 4%

J&J Beats Q1 Earnings & Sales Estimates, Raises 2026 Outlook
J&J Beats Q1 Earnings & Sales Estimates, Raises 2026 Outlook

Johnson & Johnson’s JNJ first-quarter 2026 earnings came in at $2.70 per share, which beat the Zacks Consensus Estimate of $2.67. Earnings declined 2.5% from the year-ago period.

Adjusted earnings

Can TruBridge (TBRG) Run Higher on Rising Earnings Estimates?
Can TruBridge (TBRG) Run Higher on Rising Earnings Estimates?

TruBridge (TBRG) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since

MRK, Daiichi's BLA for ADC Drug Gets FDA Priority Tag in Lung Cancer
MRK, Daiichi's BLA for ADC Drug Gets FDA Priority Tag in Lung Cancer

Merck MRK and its Japanese partner Daiichi Sankyo announced that the FDA has accepted the biologics license application (BLA) seeking approval for ifinatamab deruxtecan (I-DXd), a B7-H3-directed DXd

Can Royalty Pharma (RPRX) Keep the Earnings Surprise Streak Alive?
Can Royalty Pharma (RPRX) Keep the Earnings Surprise Streak Alive?

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Royalty Pharma

Can Qualcomm's Deepen Long-Term Tie-Up With Bosch Drive Its Shares?
Can Qualcomm's Deepen Long-Term Tie-Up With Bosch Drive Its Shares?

Qualcomm Incorporated QCOM is strengthening its presence in the automotive semiconductor industry by extending its long-standing partnership with Bosch. The deal, which earlier focused on digital

Blue Owl's Next Growth Wave: Digital Infra and Retirement Channels
Blue Owl's Next Growth Wave: Digital Infra and Retirement Channels

Blue Owl Capital Inc. OWL has spent the past year battling a tough tape for private credit and headline noise around liquidity. Still, the company enters 2026 with a broader growth playbook than

Can Rising AI Demand Boost Arista's Future Growth Prospects?
Can Rising AI Demand Boost Arista's Future Growth Prospects?

Arista Networks, Inc. ANET plays a critical and rapidly expanding role in the artificial intelligence (AI) ecosystem by providing high-performance networking solutions that power modern AI

Regeneron Boosts Cancer Pipeline Through Telix Collaboration
Regeneron Boosts Cancer Pipeline Through Telix Collaboration

Regeneron Pharmaceuticals REGN announced that it has entered into a strategic collaboration with Telix Pharmaceuticals Limited TLX to co-develop and co-commercialize next-generation

How Will Visa's Neat Partnership Help Boost Engagement and Growth?
How Will Visa's Neat Partnership Help Boost Engagement and Growth?

Visa Inc. V recently announced a new partnership with Neat to enhance the insurance and medical assistance services embedded within its cards. The collaboration underscores a broader move toward

Here's How TRV Can Retain Revenue Momentum Over the Long Term
Here's How TRV Can Retain Revenue Momentum Over the Long Term

The Travelers Companies, Inc. TRV has delivered solid financial performance over the past year, supported by consistent revenue growth. In 2025, the company generated approximately $48.8 billion in

IonQ Boosts Quantum Capabilities With Major Academic Collaborations
IonQ Boosts Quantum Capabilities With Major Academic Collaborations

IonQ IONQ continues to advance quantum networking and real-world applications through strategic collaborations with leading academic partners. In line with this, IonQ and the University of Maryland

Johnson & Johnson: A 20% Gain Looks Easy After Q1 Earnings Results
Johnson & Johnson: A 20% Gain Looks Easy After Q1 Earnings Results

Johnson & Johnson’s (NYSE: JNJ) price action entered consolidation in early March. While it may continue moving sideways or even pull back further, those moves are unlikely, given a convergence of

Can lululemon Restore Pricing Power Against Increasing Discounts?
Can lululemon Restore Pricing Power Against Increasing Discounts?

lululemon athletica inc. LULU has been taking steps to restore its pricing power; however, this will take time with disciplined execution. The pricing power weakened in 2025, reflected by higher

Mama's Creations, Inc. (MAMA) Q4 Earnings Match Estimates
Mama's Creations, Inc. (MAMA) Q4 Earnings Match Estimates

Mama's Creations, Inc. (MAMA) came out with quarterly earnings of $0.05 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.04 per share a year ago. These figures

Equity Bancshares (EQBK) Tops Q1 Earnings and Revenue Estimates
Equity Bancshares (EQBK) Tops Q1 Earnings and Revenue Estimates

Equity Bancshares (EQBK) came out with quarterly earnings of $1.32 per share, beating the Zacks Consensus Estimate of $1.15 per share. This compares to earnings of $0.9 per share a year ago. These

Has Intel's Rally Gone Too Far, or Is the Momentum Just Beginning?: https://staticx-tuner.zacks.com/images/articles/main/55/148598.webp
Has Intel's Rally Gone Too Far, or Is the Momentum Just Beginning?

Soaring nearly 70% this year, Intel INTC) stock has been on a tear thanks to a wave of positive catalysts, including AI-related partnerships, major outside investments, improving earnings, and

Zacks.com featured highlights include Matador Resources, Pampa Energia, Occidental Petroleum, First American Financial and AXIS Capital
Zacks.com featured highlights include Matador Resources, Pampa Energia, Occidental Petroleum, First American Financial and AXIS Capital

For Immediate Release

Chicago, IL – April 15, 2026 – Stocks in this week’s article are Matador Resources Co. MTDR, Pampa Energia S.A. PAM, Occidental Petroleum Corp. OXY, First American Financial

Best Value Stocks to Buy for April 15th
Best Value Stocks to Buy for April 15th

Here are three stocks with buy rank and strong value characteristics for investors to consider today, April 15: 

Darling Ingredients Inc. DAR: This sustainable ingredient company carries a Zacks